Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDOP with pegylated liposomal doxorubicin with or without rituximab in diffuse large B-cell lymphoma
ChiCTR1800020142Phase 4Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- May 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of doxorubicin and rituximab in diffuse large B-cell lymphoma (DLBCL), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Objective response rate. Started May 2013; status: recruiting.
02
Drugs
doxorubicinrituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR1800020142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800020142.